Thinking Out Loud (Blog)
Let’s get physical – (Biophysical properties of Mabs)
Hello, protein therapeutics developers! We're presenting some work in Montpellier at the Antibody Industrial Symposium (AIS) and we thought we'd share in advance of the presentation. Why? Because we thought you would want to know that Tregitope content is more...
read more
EpiVax and GAIA Vaccine Foundation Celebrate Women’s Achievements Throughout History and Across Nations
PROVIDENCE, R.I., March 9, 2018 /PRNewswire/ -- EpiVax Inc., ("EpiVax") an innovative Rhode Island-based biotechnology company, has a lot to celebrate on International Women's Day. The company, founded and led by Dr. Annie De Groot, boasts a female-majority work force...
read more
Immune Engineering Cas9: Yes We Can!
The CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated nuclease-9) system has been a model of great promise in the gene therapy research community since 2012. It was initially discovered as the adaptive immune system of certain...
read more
EpiVax Awarded Grant to Develop New Graves’ Disease Therapy
It all started in 2008, when Drs. Leslie and Annie De Groot, father and daughter, applied for a joint SBIR. Using their combined knowledge, as world leading endocrinologist and immunologist, they set out to develop a new way to treat Graves' disease, an autoimmune...
read more
The DIY Movement . . . in Cancer Vaccines
There is huge hope in personalized cancer vaccines. We are working hard to make our Ancer pipeline available for individual patients. Soon, under the aegis of EpiVax Oncology, we hope to open the door to more patients in a number of collaborative. prospective clinical trials. But for now, let’s proceed with caution, because leaping forward too quickly could be dangerous to patients. This is the promise that I made when graduating from medical school, and I stand by it: First, do no harm.
read more
Big Dog, Little Dog (Biologics) – Both Need Immunogenicity Risk Assessment
The FDA suggests that these differences in impurity found in the synthetic peptide in comparison to the RLD be justified by data that reflects that the impurity does not contain T-cell epitopes, or sequences that have an increased affinity for MHC. Well, that’s where EpiVax can help you.
read more